Biotech & Life Science Fund A/S — Credit Rating and Financial Key Figures
CVR number: 42582557
Kongevejen 365, 2840 Holte
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|
Fiscal period length | 12 | 12 | 12 | 12 |
Net sales | ||||
External services | -70.03 | - 229.89 | - 202.56 | - 174.89 |
Gross profit | -70.03 | - 229.89 | - 202.56 | - 174.89 |
EBIT | -70.03 | - 229.89 | - 202.56 | - 174.89 |
Other financial income | 84.96 | |||
Other financial expenses | - 388.85 | - 821.70 | -1.44 | - 433.72 |
Pre-tax profit | - 458.88 | -1 051.59 | - 119.04 | - 608.61 |
Net earnings | - 458.88 | -1 051.59 | - 119.04 | - 608.61 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|
Intangible assets total | ||||
Tangible assets total | ||||
Investments total | ||||
Long term receivables total | ||||
Inventories total | ||||
Short term receivables total | ||||
Other current investments | 4 191.89 | 6 842.05 | 7 259.66 | 7 623.40 |
Cash and bank deposits | 6 165.02 | 5 231.97 | 3 450.44 | 879.72 |
Cash and cash equivalents | 10 356.92 | 12 074.02 | 10 710.10 | 8 503.12 |
Balance sheet total (assets) | 10 356.92 | 12 074.02 | 10 710.10 | 8 503.12 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|
Share capital | 2 890.96 | 3 738.17 | 3 738.17 | 3 738.17 |
Retained earnings | 7 899.48 | 9 327.50 | 7 032.26 | 5 317.05 |
Profit of the financial year | - 458.88 | -1 051.59 | - 119.04 | - 608.61 |
Shareholders equity total | 10 331.56 | 12 014.08 | 10 651.39 | 8 446.61 |
Non-current liabilities total | ||||
Other non-interest bearing current liabilities | 25.36 | 59.94 | 58.71 | 56.50 |
Current liabilities total | 25.36 | 59.94 | 58.71 | 56.50 |
Balance sheet total (liabilities) | 10 356.92 | 12 074.02 | 10 710.10 | 8 503.12 |
Try the full version of our system for free
- Professional credit risk reports
- Create your own estimates for any company
- Valuation analysis
- All 400,000+ Danish companies
- See instructions

... and more!
No registration needed.